BioXcel Therapeutics, Inc. Increase Decrease In Operating Lease Liability
BioXcel Therapeutics, Inc. (BTAI) reported Increase Decrease In Operating Lease Liability of -$65.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- BioXcel Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was $0.00.
- BioXcel Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$65.00K.
- BioXcel Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$95.00K.
- BioXcel Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$96.00K.
- BioXcel Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$374.00K.
- BioXcel Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$346.00K.
- BioXcel Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$319.00K.
- BioXcel Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$293.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$65.00K 10-Q · filed 2026-08-13 | -$160.00K derived: sum of 3 quarters · filed 2026-08-13 | -$256.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$65.00K 10-Q · filed 2026-05-15 | -$160.00K derived: sum of 2 quarters · filed 2026-05-15 | -$256.00K derived: sum of 3 quarters · filed 2026-05-15 | -$349.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$191.00K derived: sum of 2 quarters · filed 2026-03-27 | -$284.00K derived: sum of 3 quarters · filed 2026-08-13 | -$374.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | -$96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$189.00K derived: sum of 2 quarters · filed 2026-08-13 | -$279.00K 10-Q · filed 2025-11-12 | -$367.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$183.00K 10-Q · filed 2026-08-13 | -$271.00K derived: sum of 3 quarters · filed 2026-08-13 | -$359.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$90.00K 10-Q · filed 2026-05-15 | -$178.00K derived: sum of 2 quarters · filed 2026-05-15 | -$266.00K derived: sum of 3 quarters · filed 2026-05-15 | -$353.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$176.00K derived: sum of 2 quarters · filed 2026-03-27 | -$263.00K derived: sum of 3 quarters · filed 2026-03-27 | -$346.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | -$88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$175.00K derived: sum of 2 quarters · filed 2025-11-12 | -$258.00K 10-Q · filed 2025-11-12 | -$340.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$170.00K 10-Q · filed 2025-08-12 | -$252.00K derived: sum of 3 quarters · filed 2025-08-12 | -$333.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$83.00K 10-Q · filed 2025-05-12 | -$165.00K derived: sum of 2 quarters · filed 2025-05-12 | -$246.00K derived: sum of 3 quarters · filed 2025-05-12 | -$325.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$163.00K derived: sum of 2 quarters · filed 2025-03-28 | -$242.00K derived: sum of 3 quarters · filed 2025-03-28 | -$319.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | -$81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$160.00K derived: sum of 2 quarters · filed 2024-11-14 | -$237.00K 10-Q · filed 2024-11-14 | -$312.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$156.00K 10-Q · filed 2024-08-06 | -$231.00K derived: sum of 3 quarters · filed 2024-08-06 | -$305.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$77.00K 10-Q · filed 2024-05-09 | -$152.00K derived: sum of 2 quarters · filed 2024-05-09 | -$226.00K derived: sum of 3 quarters · filed 2024-05-09 | -$299.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$149.00K derived: sum of 2 quarters · filed 2024-03-22 | -$222.00K derived: sum of 3 quarters · filed 2024-03-22 | -$293.00K 10-K · filed 2024-03-22 |
| 2022-09-30 | -$74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$147.00K derived: sum of 2 quarters · filed 2023-11-14 | -$218.00K 10-Q · filed 2023-11-14 | -$287.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$144.00K 10-Q · filed 2023-08-14 | -$213.00K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$71.00K 10-Q · filed 2023-05-09 | -$140.00K derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$237.00K 10-K · filed 2023-03-16 | ||
| 2021-09-30 | -$168.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | -$164.00K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |